| アブストラクト | We aimed to compare the incidence of osteoarthritis between individuals receiving metformin, the most common anti-hyperglycemic drug, and sodium-glucose co-transporter-2 inhibitors (SGLT-2is). This new-user comparative effectiveness study included individuals aged >/=40 yr in the DeSC claims database (DeSC Healthcare Inc.), with health check-up data from April 2014 to August 2023. Individuals initiated on SGLT-2is were compared with those who were initiated on metformin. The primary outcome was knee osteoarthritis, and the secondary outcomes were hip and hand osteoarthritis. After propensity score matching, Cox proportional hazards models were fitted to estimate hazard ratios (HRs) and 95% CIs. In total, 37 171 individuals were included in the study. Of these, 19 216 (68%) were male, and the mean age was 67 yr (SD, 11 yr). After propensity-score matching, the HRs for incident osteoarthritis with SGLT-2is compared with metformin were 1.03 (95% CI: 0.89-1.19) for the knee, 0.95 (95% CI: 0.63-1.43) for the hip, and 1.38 (95% CI: 0.92-2.07) for the hand. Considering the risk of developing osteoarthritis, SGLT-2is may be a viable alternative to metformin for individuals with diabetes. |
| ジャーナル名 | JBMR plus |
| Pubmed追加日 | 2025/9/22 |
| 投稿者 | Hatano, Masaki; Sasabuchi, Yusuke; Okada, Akira; Ishikura, Hisatoshi; Tanaka, Takeyuki; Saito, Taku; Tanaka, Sakae; Yasunaga, Hideo |
| 組織名 | Department of Clinical Epidemiology and Health Economics, School of Public;Health, The University of Tokyo, Tokyo 113-0033, Japan.;Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo,;Tokyo 113-0033, Japan.;Department of Real-World Evidence, Graduate School of Medicine, The University of;Tokyo, Tokyo 113-0033, Japan.;Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate;School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. |
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40978121/ |